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Abstract
Background: The risk of recurrence following ischemic stroke or transient ischemic attack is highest immediately after
the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the
early phase after ictus.
Design: The triple antiplatelets for reducing dependency after ischemic stroke trial was an international multicenter
prospective randomized open-label blinded-endpoint trial that assessed the safety and efficacy of short-term intensive
antiplatelet therapy with three agents (combined aspirin, clopidogrel and dipyridamole) as compared with guideline
treatment in acute ischemic stroke or transient ischemic attack. The primary outcome was stroke recurrence and its
severity, measured using the modified Rankin Scale at 90 days. Secondary outcomes included recurrent vascular events,
functional measures (cognition, disability, mood, quality of life), and safety (bleeding, death, serious adverse events). Data
are number (%) or mean (standard deviation, SD).
Results: Recruitment ran from April 2009 to March 2016; 3096 patients were recruited from 106 sites in four countries
(Denmark 1.6%, Georgia 2.7%, New Zealand 0.2%, UK 95.4%). Randomization characteristics included: age 69.0 (10.1)
years; male 1945 (62.8%); time onset to randomization 29.4 (11.9) h; stroke severity (National Institutes for Health
Stroke Scale) 2.8 (3.6); blood pressure 143.5 (18.2)/79.5 (11.4) mmHg; IS 2143 (69.2%), transient ischemic attack 953
(30.8%).
Conclusion: Triple antiplatelets for reducing dependency after ischemic stroke was a large trial of intensive/triple
antiplatelet therapy in acute ischemic stroke and transient ischemic attack, and included participants from four predom-
inantly Caucasian countries who were representative of patients in many western stroke services.
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Introduction
The risk of recurrence following an ischemic stroke (IS)
or transient ischemic attack (TIA) is very high over the
ﬁrst hours and days after the event,1,2 reaching up to
10% by 90 days and then declining, with a total of
about 40% by ﬁve years. Typically, recurrent events are
more severe than index events and thus increased
dependency, disability, cognitive impairment and
dementia, poor quality of life, and institutionalization
are all more likely.3,4
The long-term risk of recurrence can be reduced
through lifestyle changes (smoking cessation and redu-
cing weight, salt, saturated fat, and high alcohol intake)
and proven, cost-eﬀective pharmacological (antihyper-
tensives and statins) and surgical interventions (carotid
endarterectomy or stenting in large vessel disease).1–8
Oral anticoagulation is established for patients follow-
ing cardioembolic stroke9–12 while the majority of
patients with non-cardioembolic ischemic events
(stroke and TIA) require antiplatelet therapy.13–20 In
long-term secondary stroke prevention, dual antiplate-
let therapy with aspirin and dipyridamole reduced
recurrent events by 23% as compared with either
aspirin or dipyridamole in isolation, and without
increasing bleeding risk.17,19 However, the combination
of aspirin and clopidogrel given chronically was not
superior to either drug alone, and dual therapy resulted
in increased bleeding as compared with clopidogrel
alone.21–23
In contrast, more intensive antiplatelet therapy may
give improved prophylaxis in the acute phase of stroke
or TIA. While early antiplatelet therapy with aspirin
following acute IS is eﬀective at reducing early recur-
rence,15,16,24 dual antiplatelet therapy started within
72 h of onset reduced early recurrence risk more than
monotherapy in a meta-analysis of small studies.25
Moreover, the type of agents used was less important
than using dual rather than monotherapy. This was
supported by the ﬁndings of the large CHANCE trial;
dual antiplatelet therapy with aspirin and clopidogrel
was superior to aspirin alone in preventing stroke
recurrence by 90 days when commenced within 24 h
of minor IS or TIA.26,27 One potential beneﬁt of
using multi-antiplatelet agents is the mitigation of treat-
ment resistance seen individually with aspirin and clo-
pidogrel monotherapy.28–30
If dual antiplatelet therapy reduces stroke recurrence
following acute IS or TIA as compared to monother-
apy, then triple/intensive antiplatelet therapy with com-
bined aspirin, clopidogrel, and dipyridamole might be
even more eﬀective, providing the risk of recurrence is
high and bleeding is not excessive. Several laboratory
studies and clinical trials have assessed this con-
cept.31–35 Triple therapy in vitro was most eﬀective in
inhibiting leucocyte activation, platelet–leucocyte con-
jugation, and platelet aggregation.31–33 Phase I and II
multiway crossover trials compared short-term admin-
istration of single, dual, and triple antiplatelets and
found that aspirin and clopidogrel, with or without
dipyridamole, were most eﬀective at inhibiting platelet
function in healthy volunteers and those with previous
stroke or TIA.34,35 A parallel group trial comparing
long-term triple antiplatelet therapy with aspirin alone
in participants with stroke found that intensive treat-
ment was feasible to administer for up to 24 months,
but there was a non-signiﬁcant trend to increased
bleeding.36 In addition, chronic use of triple antiplatelet
therapy in patients with a very high risk of recurrence
following events on dual therapy appeared to be eﬀect-
ive in minimizing further events without increasing
bleeding.37
Based on these preclinical and clinical data show-
ing feasibility, tolerability, apparent safety and poten-
tial eﬃcacy for triple antiplatelet therapy, the triple
antiplatelets for reducing dependency after ischemic
stroke (TARDIS) trial tested the overall safety and
eﬃcacy of short-term intensive antiplatelet therapy in
comparison with guideline treatment. The protocol
and statistical analysis plan have been published
previously.38,39
Methods
Eligibility and consent
The full inclusion and exclusion criteria are published38
and listed in the latest version of the protocol (online
Appendix A, B). Adults aged >50 years with non-
cardioembolic TIA or stroke within 48 h of onset
were eligible. Those whose index event was a TIA had:
. Resolved limb weakness and/or dysphasia.
. Symptom duration between 10min and 24 h.
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. ABCD2 score40 >4; and/or crescendo TIA; and/or
already on dual antiplatelet therapy.
IS participants had:
. Ongoing limb weakness, or ongoing facial weakness
with resolved limb weakness; and/or dysphasia; and/
or ongoing isolated hemianopia (with positive neu-
roimaging of ischemia aﬀecting the corresponding
occipital lobe); and duration >1 h.
. Resolved limb weakness; and/or dysphasia; with
duration >24 h after onset (i.e. resolution between
24 h and randomization).
. Note: Any severity of stroke could be recruited.
Patients gave written informed consent prior to
enrolment; if they lacked capacity (e.g. due to dyspha-
sia, confusion, or reduced conscious level) then proxy
consent could be obtained from a relative, carer, or
legal representative, and if not available then independ-
ent physician proxy consent was permitted.
Neuroimaging was essential for IS to exclude intracra-
nial hemorrhage and a non-stroke diagnosis. Patients
who were thrombolyzed for stroke were eligible for
inclusion following a delay of 24 h and providing neu-
roimaging excluded secondary intracranial hemor-
rhage. Neuroimaging was performed in patients
presenting with a TIA at the discretion of local
clinicians.
Randomization and data collection
After obtaining informed consent, the local investigator
used a secure password-protected and data-encrypted
web-based randomization system to enter a participant
into the trial (a system derived from that used in the
ENOS trial41). The system recorded baseline character-
istics following validation of data using range and con-
sistency checks, and then allocated the participant to a
treatment group. To achieve optimal baseline matching
between treatment groups and ensure concealment of
allocation, randomization incorporated stratiﬁcation
(country, index event: stroke or TIA) and minimization
(on baseline prognostic factors and additional criteria
for TIA and stroke respectively, as highlighted in
Tables 2 and 3); the minimization algorithm included
a random element (simple randomization) in 5% of
patients. Stratiﬁcation and minimization allow for
improved matching at baseline, stratiﬁcation allows
variable categories to be treated as trials in their own
right, minimization increases statistical power,42 and
simple randomization reduces predictability.
Following randomization, the local investigator was
informed of the patient’s treatment allocation to
triple/intensive or guideline antiplatelet therapy; rando-
mized treatment was taken for one month, after which
participants on intensive antiplatelet therapy reverted
to guideline therapy. The minimization variables will
be used for adjustment of the primary and secondary
analyses in the main publication,39 as recommended.42
Investigational medicinal products
Trial interventions were given open label for one month
(28 or 30 days depending on treatment pack size), a
period chosen to cover the period of maximum risk of
recurrence but minimize bleeding, and comprised:
. Aspirin: loading dose 300mg then 50–150mg daily;
by oral, nasogastric tube (NGT) or rectal route.
. Clopidogrel: loading dose 300mg then 75mg daily;
by oral or NGT route.
. Dipyridamole: 225–450mg in divided doses; by oral
(as 200mg extended release capsules twice daily, or
as 25–100mg tablets three to four times daily) or
NGT (as suspension or crushed tablets three to
four times daily) route.
Participants were randomized to either:
. Intensive/triple antiplatelets (active): Combined
aspirin, clopidogrel, and dipyridamole.
. Guideline/dual or mono antiplatelet(s): Combined
aspirin and dipyridamole, or clopidogrel alone.
Throughout the trial, ﬁve protocol amendments
were made covering multiple issues. The main change
concerned an update of guidelines relating to antiplate-
let agents after stroke. When the trial commenced, the
National Institute for Health and Clinical Excellence
(NICE) recommended aspirin and dipyridamole for
secondary prevention,43 which the initial protocol
deﬁned as guideline therapy. However, signiﬁcant ran-
domized evidence supporting the use of clopidogrel for
secondary stroke prophylaxis, and widespread avail-
ability of generic inexpensive clopidogrel, resulted in
NICE updating their guidance in 2010, this recom-
mending that clopidogrel should be used ﬁrst-line
after non-cardioembolic IS.44 Therefore, the trial
protocol was updated allowing for use of either aspirin
and dipyridamole, or clopidogrel monotherapy, as the
guideline comparator (online Appendix C). Local
investigators were able to choose whether randomiza-
tion included either or both comparators, and this deci-
sion was made separately for stroke and TIA.
Outcomes
The primary and main secondary outcomes were col-
lected centrally at day 90 by an assessor based in the
national coordinating center who was blinded to treat-
ment assignment. In the ﬁrst instance, a check was
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made that the patient was still alive, either via the
general practitioner or using electronic records; the
patient and/or carer was then contacted by telephone.
Where telephone contact could not be made, outcome
information was collected using a postal question-
naire. The primary outcome was the occurrence and
severity of recurrent stroke and TIA, with severity
measured using a six-level ordered categorical scale
incorporating the modiﬁed Rankin Scale (mRS45):
fatal stroke/severe non-fatal stroke (mRS 4 or 5)/
moderate stroke (mRS 2 or 3)/mild stroke (mRS 0
or 1)/TIA/no stroke or TIA. Recurrent events and
mRS were determined centrally by telephone by a
trained assessor masked to treatment at day 90.
Local investigators assessed and reported secondary,
bleeding, and safety outcomes (including death) at
days 7 and 35, and at hospital discharge (if
admitted). Secondary outcomes were also collected
at day 90, including bleeding, death, and measures
of disability, cognition, mood, and quality of life.38
Use of the internet
The TARDIS trial used the internet to randomize and
collect data in real-time on line:
. Trial website: www.tardistrial.org.
. Secure website for real-time data entry, validation
and randomization: https://nottingham.ac.uk/
nszwww/tardis/tardistrialdb/tardis_login.php
. Demo website for local investigators to practice data
entry: https://www.nottingham.ac.uk/nszwww/
tardis/tardistrialdb-demo/
. (log-in: demoinv1, password: Nottingham; pin:
8888)
Funding and governance
The TARDIS trial received two phases of funding:
. Start-up phase (April 2009 – September 2012): fund-
ing from the British Heart Foundation: 902 patients
recruited.
. Main phase (October 2012 – March 2016, with fund-
ing through to end September 2017): funding from
the NIHR Health Technology Assessment
Programme; 2194 patients recruited. The overall
aim was to recruit a total of 4100 patients.38
The trial was supervised by a Trial Steering
Committee, with support from an International
Advisory Committee; run by a Trial Management
Committee (part of Nottingham Stroke Trials Unit);
and monitored by an independent Data Monitoring
Committee (DMC). The DMC met and assessed
safety and eﬃcacy on 13 occasions during the trial;
prior to 2016, they recommended that the trial should
continue with recruitment with no change to the proto-
col. Independent experts adjudicated brain scans and
serious adverse events, blinded to treatment.
Results
Trial delivery
Recruitment progressed with a start-up phase in a lim-
ited number of sites, and then expanded to a main
phase (Figure 1). During the trial’s progress, a
number of logistical issues arose (online Appendix C).
The DMC recommended in March 2016 that the trial
should stop recruitment; the TSC reviewed the same
data and agreed to stop recruitment, complete follow-
ups, and close the trial once data had been validated,
the database locked and analyzed, and all sites closed.
An explanation to the trial’s early stopping will be pro-
vided in the main publication.
Baseline characteristics
The following data are given as number (%) or mean
(standard deviation); 3096 participants were recruited
between April 2009 and March 2016 from 106 sites
(online Appendix D) across four countries in two con-
tinents: Denmark 51 (1.6%), Georgia 83 (2.7%),
New Zealand 7 (0.2%), and UK 2955 (95.4%) (Table
1). Four sites recruited a high number of participants
relative to other sites (Figure 2).
The baseline characteristics at the time of random-
ization are presented in Tables 2 and 3. Key features
include: age 69.0 (10.1) years; male 1945 (62.8%); time
from onset to recruitment 29.4 (11.9) h (Figure 3(a));
severity (National Institutes of Health Stroke Scale,
NIHSS) 2.8 (3.6); mean blood pressure 143.5 (18.2)/
79.5 (11.4) mmHg; IS 2143 (69.2%), TIA 953
(30.8%). In comparison with patients whose randomiz-
ing event was stroke, patients with TIA were more
likely to have pre-morbid hypertension, hyperlipidemia,
and a shorter time to randomization (Figure 3(b) and
(c)), but were less likely to be current smokers.
Table 4 shows univariate relationships between sev-
eral key baseline factors, including year of randomiza-
tion into the trial. As the trial progressed, average
NIHSS and ABCD2 scores, systolic blood pressure,
time to randomization, and proportion of strokes
(versus TIA) increased. Further, increasing time to ran-
domization was associated with increased NIHSS
score, stroke rather than TIA, and lower SBP; higher
SBP was associated with increasing age, NIHSS, and
ABCD2 scores; those with strokes were younger; and
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increasing age was associated with being female, higher
ABCD2 score and SBP, and TIA rather than stroke.
Reporting of results
Following completion of data validation, the database
will be locked and the trial unblinded and analyzed. It
is intended to present the main results in late 2016/early
2017, with the main manuscript published in parallel.
Multiple pre-speciﬁed secondary publications and ana-
lyses are described in the statistical analysis plan.39
TARDIS data will be shared with prospective indi-
vidual patient data meta-analyses:
. Antiplatelet agents in acute stroke/TIA.
. Virtual international stroke trials archive (VISTA).46
Ultimately, a subset of data will be made available
on the internet akin to the International Stroke Trial,47
and anonymized neuroimaging data will be
published.48
Discussion
TARDIS is the ﬁrst trial to assess the safety and eﬃcacy
of intensive antiplatelet therapy based on three agents
in comparison with guideline treatment; with 3096
patients, TARDIS is a large international trial. The
characteristics of the participants justify several com-
ments. First, although the trial was designed to run
internationally, contracting issues, largely related to
national sponsorship and availability of insurance
(online Appendix C), led the trial to recruit predomin-
antly a UK-population; with a large number of recruit-
ing sites, it is therefore representative primarily of UK
stroke services and their patients; however, participants
also came from three other countries with predomin-
antly Caucasian populations. Second, the proportion of
Figure 1. Recruitment curve by time.
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Table 1. Recruitment: Number of sites and patients by region
and country
Regions
Countries
No. of
sites (%)
No. of
patients (%)
Australasia
New Zealand 1 (0.9) 7 (0.2)
Europe
Denmark 2 (1.9) 51 (1.6)
Georgia 3 (2.8) 83 (2.7)
UK 100 (94.3) 2955 (95.4)
Total 106 (100) 3096 (100)
Note: Data are number and percentage.
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Table 2. Demographic characteristics and past medical history at time of randomization in TARDIS: Overall and by index event.
N All ISa TIAa
Number of patients (%) 3096 3096 (100) 2143 (69.2) 953 (30.8)
Age (years)b 3096 69.0 (10.1) 68.5 (10.1) 70.2 (9.9)
Sex, male (%)b 3096 1945 (62.8) 1356 (63.3) 589 (61.8)
Geographical regiona
Europe, rest of 3096 134 (4.3) 109 (5.1) 25 (2.6)
UK 3096 2955 (95.4) 2032 (94.8) 923 (96.9)
World, rest of 3096 7 (0.2) 2 (0.1) 5 (0.5)
Ethnicity (%)
White 3096 2939 (94.9) 2024 (94.4) 9156 (96.0)
Black 3096 63 (2.0) 58 (2.7) 5 (0.5)
East Asian 3096 2 (0.1) 2 (0.1) 0 (0.0)
South Asian 3096 46 (1.5) 29 (1.4) 17 (1.8)
South East Asian 3096 1 (0.0) 0 (0.0) 1 (0.1)
Other Asian 3096 11 (0.4) 7 (0.3) 4 (0.4)
Mixed: White and Black 3096 9 (0.3) 6 (0.3) 3 (0.3)
(continued)
Figure 2. Recruitment by hospital sites.
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Table 2. Continued
N All ISa TIAa
Mixed: Other 3096 2 (0.1) 2 (0.1) 0 (0.0)
Other 3096 12 (0.4) 7 (0.3) 5 (0.5)
Not Stated 3096 11 (0.4) 8 (0.4) 3 (0.3)
Dominant hand, Right (%) 3058 2798 (91.5) 1918 (90.6) 880 (93.5)
Source of referral
Emergency department 3096 2037 (65.8) 1446 (67.5) 591 (62.0)
Outpatient clinic 3096 129 (4.2) 38 (1.8) 91 (9.5)
Ambulance 3096 586 (18.9) 435 (20.3) 151 (15.8)
General practitioner 3096 156 (5.0) 87 (4.1) 69 (7.2)
Inpatient ward 3096 94 (3.0) 55 (2.6) 39 (4.1)
Other 3096 94 (3.0) 82 (3.8) 12 (1.3)
Pre-stroke mRS [/6] 3096 0.0 [0.0, 0.0] 0.0 [0.0, 0.0] 0.0 [0.0, 0.0]
0 (%) 3094 2604 (84.2) 1781 (83.1) 823 (86.5)
1–2 3094 490 (15.8) 362 (16.9) 128 (13.5)
Medical history (%)
Hypertensionb 3096 1826 (59.0) 1241 (57.9) 585 (61.4)
Antihypertensives 3096 1742 (56.3) 1181 (55.1) 561 (58.9)
Hyperlipidaemia 2972 1315 (44.2) 874 (42.5) 441 (48.2)
Lipid lowering 3096 1387 (44.8) 929 (43.4) 458 (48.1)
Diabetes mellitus 3096 590 (19.1) 418 (19.5) 172 (18.0)
Treatment
Insulin 3096 59 (1.9) 47 (2.2) 12 (1.3)
Oral agents 3096 347 (11.2) 232 (10.8) 115 (12.1)
Both 3096 79 (2.6) 64 (3.0) 15 (1.6)
Neither 3096 104 (3.4) 74 (3.5) 30 (3.1)
Antiplatelet agent
Aspirin 3096 816 (26.4) 558 (26.0) 258 (27.1)
Aspirin/dipyridamole 3096 85 (2.7) 45 (2.1) 40 (4.2)
Clopidogrel 3096 162 (5.2) 117 (5.5) 45 (4.7)
Other 3096 17 (0.5) 14 (0.7) 3 (0.3)
(continued)
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Table 2. Continued
N All ISa TIAa
Heparin 3096 7 (0.2) 5 (0.2) 2 (0.2)
Glycoprotein inhibitor 3096 0 (0.0) 0 (0.0) 0 (0.0)
Gastroprotection (PPI/H2A) 3096 803 (25.9) 539 (25.2) 264 (27.7)
AF, current/previous 3096 1 (0.0) 0 (0.0) 1 (0.1)
Stroke 3096 349 (11.3) 255 (11.9) 94 (9.9)
Transient ischemic attack 3096 337 (10.9) 190 (8.9) 147 (15.4)
Ischemic heart disease 3096 402 (13.0) 289 (13.5) 113 (11.9)
Peripheral arterial disease 3062 70 (2.3) 50 (2.4) 20 (2.1)
Family history of young stroke 2901 170 (5.9) 120 (6.0) 50 (5.6)
Smoking, current (%) 3052 784 (25.7) 627 (29.7) 157 (16.7)
Alcohol intake, high (>21 upw) 3001 291 (9.7) 211 (10.2) 80 (8.6)
Qualifying event, final diagnosis (%)c
Ischemic stroke 3095 2220 (71.7) 2055 (95.9) 165 (17.3)
TIA 3095 838 (27.1) 64 (3.0) 774 (81.2)
Crescendo 773 155 (20.1) 0 (0.0) 155 (20.1)
Dual antiplatelets 838 36 (4.3) 2 (3.1) 34 (4.4)
Non-stroke/TIA 3095 36 (1.2) 23 (1.1) 13 (1.4)
Onset to randomization [h]b 3096 29.3 [21.8, 39.6] 32.1 [24.7, 41.2] 24.2 [17.5, 29.6]
By qualifying event
Ischemic stroke 2143 32.1 [24.7, 41.2] 32.1 [24.7, 41.2] –
TIA 953 24.2 [17.5, 29.6] – 24.2 [17.5, 29.6]
Time, h (%)
12 3096 314 (10.1) 151 (7.0) 163 (17.1)
13–24 3096 651 (21.0) 355 (16.6) 296 (31.1)
25–48 3096 2124 (68.6) 1630 (76.1) 494 (51.8)
>48d 3096 7 (0.2) 7 (0.3) 0 (0.0)
Mean (SD) 3096 29.4 (11.9) 31.8 (11.4) 24.1 (11.1)
aStratification variable.
bMinimisation variable.
cFinal hospital diagnosis may vary from diagnosis used at time of randomization
d Protocol violation.
AF: atrial fibrillation; H2A: H2 antagonist; mRS: modified Rankin Scale; PPI: proton pump inhibitor; TIA: transient ischemic attack; upw: units per week.
Note: Data are number (percentage), median [interquartile range] or mean (standard deviation).
Validation is ongoing and some data may undergo minor changes prior to data lock. These data have been partially validated and may undergo minor
changes prior to data lock.
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Table 3. Clinical characteristics at time of randomization in TARDIS: Overall and by index event
N All ISa TIAa
Number of patients 3096 3096 2143 953
Lesion side, right (%) 2789 1429 (51.2) 1021 (51.2) 408 (51.5)
Weakness (%) 3095 2789 (90.1) 1996 (93.1) 793 (83.3)
Sensory loss (%) 3096 1066 (34.4) 823 (38.4) 243 (25.5)
Dysphasia (%) 3096 1007 (32.5) 593 (27.7) 414 (43.4)
Isolated 3096 160 (5.2) 58 (2.7) 102 (10.7)
Neglect (%) 3096 331 (10.7) 299 (14.0) 32 (3.4)
Hemianopia (%) 3096 302 (9.8) 268 (12.5) 34 (3.6)
Isolated 3096 16 (0.5) 16 (0.7) 0 (0.0)
Dysarthria (%) 3096 1279 (41.3) 959 (44.8) 320 (33.6)
Posterior circulation (%) 3096 287 (9.3) 245 (11.4) 42 (4.4)
NIHSS (/42)b 3096 2.8 (3.6) 4.0 (3.8) 0.2 (0.7)
ABCD2 score [/7] 3096 5.0 [5.0, 6.0] 6.0 [5.0, 6.0] 5.0 [5.0, 6.0]
GCS [/15] 3096 15.0 [15.0, 15.0] 15.0 [15.0, 15.0] 15.0 [15.0, 15.0]
OCSP (%)50
Total anterior y 3096 180 (5.8) 166 (7.7) 14 (1.5)
Partial anterior 3096 1412 (45.6) 837 (39.1) 575 (60.3)
Lacunar 3096 1289 (41.6) 952 (44.4) 337 (35.4)
Posterior 3096 213 (6.9) 188 (8.8) 25 (2.6)
TOAST (%)c
Cardioembolic 3051 133 (4.4) 108 (5.1) 25 (2.7)
Large vessel 3051 490 (16.1) 389 (18.4) 101 (10.8)
Small vessel 3051 1225 (40.2) 896 (42.3) 329 (35.3)
Mixed 3051 22 (0.7) 19 (0.9) 3 (0.3)
Other 3051 1181 (38.7) 706 (33.3) 475 (50.9)
Hemodynamics
Systolic BP (mmHg) b 3096 143.5 (18.2) 143.2 (18.2) 144.2 (18.0)
Diastolic BP (mmHg) 3096 79.5 (11.4) 79.6 (11.5) 79.2 (11.1)
Heart rate (bpm) 3096 73.1 (12.6) 73.6 (12.7) 71.8 (12.3)
Feeding status (%)
Normal diet 3096 2874 (92.8) 1929 (90.0) 945 (99.2)
(continued)
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stroke patients recruited as compared with TIAs was
higher than intended; the proportion of stroke
increased as the trial progressed, probably related to
closure of other large stroke trials such as ENOS and
SO2S.
41,49 Third, in addition to more stroke patients
being recruited over time, their severity, SBP, and
time to randomization also increased, this reﬂecting dif-
ferences in the types of participants recruited by sites
who joined the trial later. Last, TIA patients were
recruited much earlier than those with stroke as their
index event, which may have implications for both eﬃ-
cacy and risk.
Although TARDIS is large, and deﬁnitive and sig-
niﬁcant results may help drive changes in clinical prac-
tice, it will still be necessary to merge individual patient
data from TARDIS with other large trials of antiplate-
let agents in acute IS and TIA to fully assess their
eﬀects in diﬀerent patient subgroups.
TARDIS investigators
Trial Steering Committee (UK)
Independent members: Helen Rodgers (Newcastle, TSC
Chair), Ahamad Hassan (Leeds), Christine Roﬀe
(Stoke-on-Trent), Craig Smith (Salford), William D
Toﬀ (Leicester).
Grant holders: Philip M Bath (Nottingham, Chief
Investigator), Rob Dineen (Nottingham,
Neuroradiology Lead), Lelia Duley (Nottingham),
Table 3. Continued
N All ISa TIAa
Soft diet 3096 168 (5.4) 161 (7.5) 7 (0.7)
NGT fed 3096 51 (1.6) 50 (2.3) 1 (0.1)
PEG/RIG fed 3096 3 (0.1) 3 (0.1) 0 (0.0)
IV/SC fluids 3096 0 (0.0) 0 (0.0) 0 (0.0)
Nothing 3096 0 (0.0) 0 (0.0) 0 (0.0)
Hemoglobin (g/L) 3096 141.8 (14.7) 142.1 (15.0) 141.1 (14.2)
Blood glucose (mmol/L) 3050 6.8 (2.5) 6.9 (2.7) 6.5 (2.0)
Temperature (C) 3058 36.5 (0.5) 36.5 (0.5) 36.5 (0.5)
Weight (Approx. kg) 3048 75.3 (16.6) 75.5 (16.5) 75.0 (16.9)
Brain imaging (%)
Normal/no lesion 3089 1561 (50.5) 959 (44.9) 602 (63.2)
Ischaemic stroke 3089 1378 (44.6) 1175 (55.0) 203 (21.3)
Non stroke 3089 6 (0.2) 3 (0.1) 3 (0.3)
No brain scan 3089 144 (4.7) 0 (0.0) 144 (15.1)
Thrombolysisb 3096 341 (11.0) 336 (15.7) 5 (0.5)
Time [h] 341 2.3 [1.8, 3.0] 2.3 [1.8, 3.0] 2.3 [1.8, 2.5]
aStratification variable.
bMinimisation variable.
cIschaemic patients only.
ABCD2: age, blood pressure, clinical features, duration, diabetes; BP: blood pressure; bpm: beats per minute; GCS: Glasgow coma scale; IV: intra-
venous; NGT: nasogastric tube; NIHSS: National Institutes of Health Stroke Scale; OCSP: Oxford community stroke project; PEG: percutaneous
endoscopic gastrostomy; RIG: radiologically inserted gastrostomy; SC: subcutaneous; TIA: transient ischemic attack; TOAST: Trial of ORG 10172 in
acute stroke treatment.
Note: Data are number (percentage), median [interquartile range] or mean (standard deviation). These data have been partially validated and may
undergo minor changes prior to data lock.
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Figure 3. Histogram of recruitment by time from onset to randomization for: (a) all patients (median 29.3 h), (b) stroke (median
32.0 h), and (c) TIA (median 24.2 h).
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Stan Heptinstall (Nottingham, Platelet Expert),
Marilyn James (Nottingham, Health Economic Lead),
Hugh S Markus (Cambridge), Stuart Pocock (London,
Statistical Lead), Thompson G Robinson (Leicester),
Nikola Sprigg (Nottingham, Deputy Chief
Investigator), Graham S Venables (Sheﬃeld).
Patient representative: Chibeka Kasonde
(Nottingham).
Sponsor’s representative: Angela Shone (University
of Nottingham).
International Advisory Committee
Denmark – Hanne Christensen (Copenhagen),
Georgia -Maia Beridze (Tblisi), New Zealand – Anna
Ranta (Wellington).
Independent Data Monitoring Committee
Ian Ford (Glasgow, UK; Chair), Didier Leys (Lille,
France), Cathie Sudlow (Edinburgh, UK), Matthew
Walters (Glasgow, UK).
Independent Events (outcome, SAE) Adjudicator
Nikola Sprigg (Nottingham, UK), Marc Randall
(Leeds, UK), Wayne Sunman (Nottingham, UK).
Neuroimaging Adjudicators
Rob Dineen (Nottingham, UK), Alessandro Adami
(Verona, Italy), Lesley Cala (Perth, Australia), Ana
Casado (Edinburgh, UK), Rebecca Gallagher (Derby,
UK), David Swienton (Leicester, UK).
Platelet substudy
Stan Heptinstall, Sue Fox, JaneMay (Nottingham, UK).
Trial management committee
Senior Trial Managers: Sally Utton (2012–2014), Di
Havard (2015–2016).
Trial Manager: Hayley Foster (2013–2016).
UK Coordinators: Margaret Adrian (2009–2016),
Tanya Payne (2009–2015), Alice Durham (2013–
2014), Harriet Howard (2014–2015), Michael Stringer
(2014–2016), Jamie Longmate (2015–2016).
International Coordinators: Sharon Ellender (2009–
2013), Alice Durham (2013–2014), Sarah Grant
(2013–2014), Joanne Keeling (2014–2016).
Outcome Coordinators: Sharon Ellender (2009–
2013), Lynn Stokes (2010–2012), Patrick Cox (2011–
2013), Judith Clarke (2012), Lyndsey Cobane (2012–
2014), Kathy Whittamore (2013–2014), Joanne
Figure 3. continued.
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Keeling (2013–2016), Jennifer Smithson (2014–2016),
James Kirby (2015–2016), Gemma Walker
(2015–2016).
Statisticians: Michael Tracy (2009–2010), Cheryl
Renton (2009–2012), Cyrille Correia (2011), Lydia
Fox (2012–2013), Aimee Houlton (2012–2013), Katie
Flaherty (2013–2016), Polly Scutt (2013–2016), Lisa
Woodhouse (2013–2016).
Programming/database management: Richard
Dooley, Liz Walker (Nottingham, UK).
Physicians: Tim England (2009), Chamilla
Geeganage (2009–2012), Sandeep Ankolekar (2009–
2011), Kailash Krishnan (2012–2015), Jason Appleton
(2015–2016).
Data managers: Lida Kaur (2009–2010), Tanya
Jones (2010–2013), Clare Randall (2011–2012), Dawn
Hazle (2012–2016), Mark Sampson (2013–2016).
Finance: Wim Clarke (2009–2016).
Secretaries: Marilyn Stonham (2011), Susan
Blencowe (2012–2013), Yvonne Smallwood (2012–
2016), Lauren Dunn (2013–2014), Monika Kowalczyk
(2014–2016), Patricia Robinson (2015–2016).
Administrators (temporary): Sarah Bull (2013),
Georgina Phillips (2013), Harry Banks (2013–2014),
Esther Akanya (2014), Sean McLoughlin (2015),
Richard Barks (2015–2016).
Sites
The list of participating local investigators, sites and
trial coordinating staﬀ is given in online Appendix D.
Acknowledgements
We thank all the patients, and their carers, for participating in
the trial. We also thank the members of the independent Data
Monitoring Committee who supervised safety from the begin-
ning to end of trial.
Declaration of conflicting interests
Theauthor(s) declared the followingpotential conﬂicts of interest
with respect to the research, authorship, and/or publication of
this article: PMB declares advisory board/fees from Athersys,
Covidien, Nestle, Phagenesis, and ReNeuron; he is an unpaid
advisor to Platelet Solutions Ltd. HC declares advisory board/
fees from Bayer, Boehringer-Ingelheim, BMS, Astra-Zeneca,
Amgen, Covidien. SH is a founder and stockholder of Platelet
Solutions Ltd. HSM declares fees from AstraZeneca. TGR
declares advisory board/ fees from Bayer, Boehringer
Ingelheim and Daiichi Sankyo. JPA, MB, RAD, LD, TJE, MJ,
KK, SP, AR,KF, PS, GSV, LJW andNSmade no declarations.
Funding
The author(s) disclosed receipt of the following ﬁnancial sup-
port for the research, authorship, and/or publication of this
article: The TARDIS start-up phase was funded by the
British Heart Foundation (grant PG/08/083/25779, 1 AprilT
a
b
le
4
.
U
n
iv
ar
ia
te
co
rr
e
la
ti
o
n
s
b
e
tw
e
e
n
b
as
e
lin
e
ch
ar
ac
te
ri
st
ic
s
fo
r:
ag
e
,
se
x
,
se
ve
ri
ty
(N
IH
SS
,
A
B
C
D
2
),
q
u
al
ify
in
g
ev
e
n
t
ty
p
e
(I
S,
T
IA
),
sy
st
o
lic
b
lo
o
d
p
re
ss
u
re
(S
B
P
),
ti
m
e
to
ra
n
d
o
m
iz
at
io
n
,
an
d
ye
ar
o
f
ra
n
d
o
m
iz
at
io
n
.
C
o
rr
e
la
ti
o
n
s
b
y
p
o
in
t
b
is
e
ri
al
o
r
P
e
ar
so
n
’s
te
st
s;
d
at
a
ar
e
re
gr
e
ss
io
n
co
e
ff
ic
ie
n
t
(p
va
lu
e
)
A
ge
Se
x
,
M
al
e
N
IH
SS
A
B
C
D
2
E
ve
n
t
ty
p
e
,
St
ro
ke
SB
P
O
n
se
t
to
ra
n
d
o
m
iz
at
io
n
Y
e
ar
o
f
ra
n
d
o
m
iz
at
io
n
A
ge
X
0
.1
3
4
(<
0
.0
0
1
)
0
.0
1
2
(0
.5
2
)
0
.2
7
1
(<
0
.0
0
1
)
0
.0
7
9
(<
0
.0
0
1
)
0
.0
8
5
(<
0
.0
0
1
)
0
.0
2
3
(0
.2
1
)
0
.0
1
7
(0
.3
4
)
Se
x
0
.1
3
4
(<
0
.0
0
1
)
X
0
.0
2
0
(0
.2
6
)
0
.0
0
8
(0
.6
7
)
0
.0
1
4
(0
.4
3
)
0
.0
1
9
(0
.2
9
)
0
.0
1
1
(0
.5
6
)
0
.0
1
2
(0
.4
9
)
N
IH
SS
-0
.0
1
2
(0
.5
2
)
0
.0
2
0
(0
.2
6
)
X
0
.1
5
1
(<
0
.0
0
1
)
0
.4
8
5
(<
0
.0
0
1
)
0
.0
3
9
(0
.0
3
1
)
0
.1
6
7
(<
0
.0
0
1
)
0
.0
4
7
(0
.0
0
8
4
)
A
B
C
D
2
0
.2
7
1
(<
0
.0
0
1
)
0
.0
0
8
(0
.6
7
)
0
.1
5
1
(<
0
.0
0
1
)
X
0
.1
9
6
(<
0
.0
0
1
)
0
.4
2
7
(<
0
.0
0
1
)
0
.0
1
6
(0
.3
8
)
0
.0
4
7
(0
.0
0
9
5
)
T
yp
e
0
.0
7
9
(<
0
.0
0
1
)
0
.0
1
4
(0
.4
3
)
0
.4
8
5
(<
0
.0
0
1
)
0
.1
9
6
(<
0
.0
0
1
)
X
0
.0
2
4
(0
.1
9
)
0
.2
9
7
(<
0
.0
0
1
)
0
.1
2
7
(<
0
.0
0
1
)
SB
P
0
.0
8
5
(<
0
.0
0
1
)
0
.0
1
9
(0
.2
9
)
0
.0
3
9
(0
.0
3
1
)
0
.4
2
7
(<
0
.0
0
1
)
0
.0
2
4
(0
.1
9
)
X
0
.1
1
2
(<
0
.0
0
1
)
0
.0
6
2
(<
0
.0
0
1
)
T
im
e
0
.0
2
3
(0
.2
1
)
0
.0
1
1
(0
.5
6
)
0
.1
6
7
(<
0
.0
0
1
)
0
.0
1
6
(0
.3
8
)
0
.2
9
7
(<
0
.0
0
1
)
0
.1
1
2
(<
0
.0
0
1
)
X
0
.0
6
4
(<
0
.0
0
1
)
Y
e
ar
0
.0
1
7
(0
.3
4
)
0
.0
1
2
(0
.4
9
)
0
.0
4
7
(0
.0
0
8
4
)
0
.0
4
7
(0
.0
0
9
5
)
0
.1
2
7
(<
0
.0
0
1
)
0
.0
6
2
(<
0
.0
0
1
)
0
.0
6
4
(<
0
.0
0
1
)
X
A
B
C
D
2
:
ag
e
,
b
lo
o
d
p
re
ss
u
re
,
cl
in
ic
al
fe
at
u
re
s,
d
u
ra
ti
o
n
,
d
ia
b
e
te
s;
IS
:
is
ch
e
m
ic
st
ro
ke
;
N
IH
SS
:
N
at
io
n
al
In
st
it
u
te
s
o
f
H
e
al
th
St
ro
ke
Sc
al
e
;
SB
P
:
sy
st
o
lic
b
lo
o
d
p
re
ss
u
re
;
T
IA
:
tr
an
si
e
n
t
is
ch
e
m
ic
at
ta
ck
.
International Journal of Stroke, 0(0)
Bath et al. 13
2009 – 30 September 2012); the TARDIS main phase is
funded by the National Institute of Health Research
(NIHR) Heath Technology Assessment (HTA) Program
(grant 10/104/24, 1 October 2012 – 30 September 2017,
http://www.nets.nihr.ac.uk/projects/hta/1010424). This
paper presents independent research funded by the National
Institute for Health Research (NIHR). The views expressed
are those of the author(s) and not necessarily those of the
NHS, the NIHR or the Department of Health.
PMB is Stroke Association Professor of Stroke
Medicine; PMB and TGR are NIHR Senior Investigators.
References
1. Rothwell PM, Giles MF, Chandratheva A, et al. Effect of
urgent treatment of transient ischaemic attack and minor
stroke on early recurrent stroke (EXPRESS study): a pro-
spective population-based sequential comparison. Lancet
Neurol 2007; 370: 1432–1442.
2. Lavallee PC, Meseguer E, Abboud H, et al. A transient
ischaemic attack clinic with round-the-clock access
(SOS0TIA): feasibility and effects. Lancet Neurol 2007;
6: 953–960.
3. PATS Collaborating Group. Post-stroke antihyperten-
sive treatment study. A preliminary result. Chin Med J
1995; 108: 710–717.
4. PROGRESS Collaborative Group. Randomised trial of a
perindopril-based blood-pressure-lowering regimen
among 6,105 individuals with previous stroke or transient
ischaemic attack. Lancet 2001; 358: 1033–1041.
5. Rashid P, Leonardi-Bee J and Bath P. Blood pressure
reduction and the secondary prevention of stroke and
other vascular events: a systematic review. Stroke 2003;
34: 2741–2749.
6. Heart Protection Study Collaborative Group. Effects of
cholesterol-lowering with simvastatin on stroke and other
major vascular events in 20536 people with cerebrovascu-
lar disease or other high-risk conditions. Lancet 2004;
363: 757–767.
7. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP
and Barnett HJM; for the Carotid Endarterectomy
Trialists Collaboration. Endarterectomy for symptomatic
carotid stenosis in relation to clinical subgroups and
timing of surgery. Lancet 2004; 363: 915–924.
8. The Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) Investigators. High-dose
atorvastatin after stroke or transient ischemic attack.
N Engl J Med 2006; 355: 549–559.
9. EAFT (European Atrial Fibrillation Trial) Study Group.
Secondary prevention in non-rheumatic atrial fibrillation
after TIA or minor stroke. Lancet 1993; 342: 1255–1262.
10. Diener HC, Aichner F, Bode C, et al. Primary and sec-
ondary prevention of cerebral ischemia Joint Guidelines
of the German Society of Neurology (DGN) and German
Stroke Society (DSG). Aktuel Neurol 2010; 37: E2–E22.
11. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban
compared with warfarin in patients with atrial fibrillation
and previous stroke or transient ischaemic attack: a sub-
group analysis of ROCKET AF. Lancet Neurol 2012; 11:
315–322.
12. Easton JD, Lopes RD, Bahit MC, et al. Apixaban com-
pared with warfarin in patients with atrial fibrillation and
previous stroke or transient ischaemic attack: a subgroup
analysis of the ARISTOTLE trial. Lancet Neurol 2012;
11: 503–511.
13. Farrell B, Godwin J, Richards S and Warlow C. The
United Kingdom transient ischaemic attack (UK-TIA)
aspirin trial: final results. J Neurol Neurosurg Psychiatr
1991; 54: 1044–1054.
14. The Dutch TIA Trial Study Group. A comparison of two
doses of aspirin (30 mg vs. 283 mg a day) in patients after
a transient ischemic attack or minor ischemic stroke.
N Engl J Med 1991; 325: 1261–1266.
15. International Stroke Trial Collaborative Group. The
International Stroke Trial (IST); a randomised trial of
aspirin, subcutaneous heparin, both, or neither among
19435 patients with acute ischaemic stroke. Lancet
1997; 349: 1569–1581.
16. CAST (Chinese Acute Stroke Trial) Collaborative
Group. CAST: randomised placebo-controlled trial of
early aspirin use in 20,000 patients with acute ischaemic
stroke. Lancet 1997; 349: 1641–1649.
17. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P and
Lowenthal A. European stroke prevention study .2.
Dipyridamole and acetylsalicylic acid in the secondary
prevention of stroke. J Neurol Sci 1996; 143: 1–13.
18. Leonardi-Bee J, Bath PM, Bousser MG, et al.
Dipyridamole for preventing recurrent ischemic stroke
and other vascular events: a meta-analysis of individual
patient data from randomized controlled trials. Stroke
2005; 36: 162–168.
19. The ESPRIT Study Group. Aspirin plus dipyridamole
versus aspirin alone after cerebral ischaemia of arterial
origin (ESPRIT): randomised controlled trial. Lancet
2006; 367: 1665–1673.
20. Halkes PH, Gray LJ, Bath PM, et al. Dipyridamole plus
aspirin versus aspirin alone in secondary prevention after
TIA or stroke: a meta-analysis by risk. J Neurol
Neurosurg Psychiatr 2008; 79: 1218–1223.
21. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and
aspirin versus aspirin alone for the prevention of athero-
thrombotic events. N Engl J Med 2006; 354: 1706–1717.
22. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin
and clopidogrel compared with clopidogrel alone after
recent ischaemic stroke or transient ischaemic attack in
high-risk patients (MATCH): randomised, double-blind,
placebo-controlled trial. Lancet 2004; 364: 331–337.
23. Bath PMW. Role of aspirin in MATCH. Lancet 2004;
364: 1662.
24. Rothwell P, Algra A, Chen Z, Diener H, Norrving B and
Mehta Z. Effects of aspirin on risk and severity of early
recurrent stroke after transient ischaemic attack and
ischaemic stroke: time-course analysis of randomised
trials. Lancet 2016; 388: 365–375.
25. Geeganage CM, Diener HC, Algra A, et al. Dual or
mono antiplatelet therapy for patients with acute ische-
mic stroke or transient ischemic attack: systematic review
and meta-analysis of randomized controlled trials. Stroke
2012; 43: 1058–1066.
International Journal of Stroke, 0(0)
14 International Journal of Stroke 0(0)
26. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with
aspirin in acute minor stroke or transient ischemic
attack. N Engl J Med 2013; 369: 11–19.
27. Wong KSL, Wang Y, Leng X, et al. Early dual versus
mono antiplatelet therapy for acute non-cardioembolic
ischemic stroke or transient ischemic attack: an updated
systematic review and meta-analysis. Circulation 2013;
128: 1656–1666.
28. Michelson AD, Cattaneo M, Eikelboom JW, et al.
Aspirin resistance: position paper of the working grop
on aspirin resistance. J Thromb Haemost 2005; 3:
1309–1311.
29. Siller-Matula J, Schror K, Wojta J and Huber K.
Thienopyridines in cardiovascular disease: Focus on clo-
pidogrel resistance. Thromb Haemost 2007; 97: 385–393.
30. Serebruany V, Cherala G, Williams C, et al. Association
of platelet responsiveness with clopidogrel metabolism:
role of compliance in the assessment of ‘‘resistance’’.
Am Heart J 2009; 158: 925–932.
31. Zhao L, Bath P and Heptinstall S. Effects of combining
three different antiplatelet agents on platelets and leuko-
cytes in whole blood in vitro. Br J Pharmacol 2001; 134:
353–358.
32. Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S and
Losche W. The GPIIb/IIIa antagonist eptifibatide mark-
edly potentiates platelet-leukocyte interaction and tissue
factor expression following platelet activation in whole
blood in vitro. Platelets 2002; 13: 401–406.
33. Zhao L, Bath PMW, Fox S, et al. The effects of GPII-IIIa
antagonists and a combination of three other antiplatelet
agents on platelet-leukocyte interactions. Curr Med Res
Opin 2003; 19: 178–186.
34. Zhao L, Fletcher S, Weaver C, et al. Effects of aspirin,
clopidogrel and dipyridamole administered singly and in
combination on platelet and leucocyte function in normal
volunteers and patients with prior ischaemic stroke.
Thromb Haemost 2005; 93: 527–534.
35. Zhao L, Gray LJ, Leonardi-Bee J, Weaver CS,
Heptinstall S and Bath PM. Effect of aspirin, clopidogrel
and dipyridamole on soluble markers of vascular func-
tion in normal volunteers and patients with prior ischae-
mic stroke. Platelets 2006; 17: 100–104.
36. Sprigg N, Gray LJ, England T, et al. A randomised con-
trolled trial of triple antiplatelet therapy (aspirin, clopi-
dogrel and dipyridamole) in the secondary prevention of
stroke: safety, tolerability and feasibility. PLoS One 2008;
3: e2852.
37. Willmot M, Zhao L, Heptinstall S and Bath PMW. Triple
antiplatelet therapy for secondary prevention of recurrent
ischemic stroke. J Stroke Cerebrovasc Dis 2004; 13:
138–140.
38. TARDIS Trial Investigators. Safety and eff icacy of
intensive vs. guideline antiplatelet therapy in high-riskpa-
tients with recent ischemic stroke or transient ischemic
attack: rationale and design of the triple antiplatelets
for reducing dependency after ischaemic
stroke(TARDIS) trial (ISRCTN47823388). Int J Stroke
2015; 10: 1159–1165.
39. Bath PM, Robson K, Woodhouse LJ, et al. Statistical
analysis plan for the ‘Triple Antiplatelets for Reducing
Dependency after Ischaemic Stroke’ (TARDIS) trial. Int
J Stroke 2015; 10: 449–451.
40. Perry JJ, Sharma M, Sivilotti ML, et al. Prospective val-
idation of the ABCD2 score for patients in the emergency
department with transient ischemic attack. Canad Med
Assoc J 2011; 183: 1137–1145.
41. The ENOS Trial Investigators. Efficacy of nitric oxide,
with or without continuing antihypertensive treatment,
for management of high blood pressure in acute stroke
(ENOS): a partial-factorial randomised controlled trial.
Lancet 2015; 385: 617–628.
42. Weir CJ and Lees KR. Comparison of stratification and
adaptive methods for treatment allocation in an acute
stroke clinical trial. Stat Med 2003; 22: 705–726.
43. (NICE) NIfHaCE. Clopidogrel and modifiedrelease
dipyridamole in the prevention of occlusive vascular
events National Institute for Health and Clincal
Excellence, 2005.
44. NICE. Clopidogrel and modified release dipyridamole
for the prevention of occlusive vascular events, 2010
(December 2010).
45. Lees KR, Bath PMW, Schellinger PD, et al.
Contemporary outcome measures in acute stroke
research: choice of primary outcome measure. Stroke
2012; 43: 1163–1170.
46. Ali M, Bath PM, Curram J, et al. The virtual inter-
national stroke trials archive. Stroke 2007; 38: 1905–1910.
47. Sandercock PA, Niewada M and Czlonkowska A. The
international stroke trial database. Trials 2011; 12: 101.
48. Wardlaw J, Bath P, Sandercock P, et al. The NeuroGrid
stroke examplar clinical trial protocol. Int J Stroke 2007;
2: 63–69.
49. Roffe C, Navatte T, Crome P, et al. The Stroke Oxygen
Study (SO2S) – a multi-center, study to assess whether
routine oxygen treatment in the first 72 hours after a
stroke improves long-term outcome: study protocol for
a randomized controlled trial. Trials 2014; 15: 99.
50. Bamford J, Sandercock P, Dennis M, Burn J and Warlow
C. Classification and natural history of clinically identi-
fiable subtypes of cerebral infarction. Lancet 1991; 337:
1521–1526.
International Journal of Stroke, 0(0)
Bath et al. 15
